



**Proteomics International**

LABORATORIES LTD

ASX Release

22 July 2021

ASX code: PIQ

## **Proteomics International engages Abcam to manufacture PromarkerD reagents**

- Global life science company Abcam plc engaged to produce reagents for Proteomics International's immunoassay version of the PromarkerD test for diabetic kidney disease
- Abcam is a leader in the supply of life science research tools and reagents, including supply to companies who develop and market diagnostic solutions around the world
- Working with Abcam will help streamline test production, allowing Proteomics International to service anticipated demand for PromarkerD worldwide
- The engagement signifies Proteomics International achieving another milestone as it continues the path towards commercialisation of PromarkerD in global markets

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has engaged global life science company Abcam plc (AIM:ABC; Nasdaq:ABCM) (Abcam) to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test for the early detection of kidney disease in patients with type 2 diabetes.

Under the terms of the commercial fee-for-service agreement, Abcam will produce the specialist reagents required for the immunoassay version of the PromarkerD test, which is designed to be used on standard platforms found in most clinical pathology laboratories. These reagents include synthetic protein standards and antibodies, which are used to detect the protein biomarkers in the blood associated with diabetic kidney disease.

Working with Abcam, Proteomics International recently completed production of recombinant versions of the relevant antibodies. This is expected to result in a stable, more consistent product over the long term, improve scale-up, and help secure future supply chains.

Proteomics International Managing Director Dr Richard Lipscombe said by implementing these processes and securing an agreement with Abcam, the Company's commercialisation strategy for successfully delivering PromarkerD to global markets was on track, with the steps including accreditation and regulatory approvals, manufacture and kit assembly, and distribution.

*"Having recently achieved ISO 13485 registration for our organisation [ASX: 23 April], which enables internationally certified manufacture of the PromarkerD immunoassay, we are now building our production capacity to meet the anticipated worldwide demand for the PromarkerD test."*

*"By engaging global manufacturing partners, such as Abcam who are experts in the manufacturing processes we require, we are building a robust framework that will help accelerate the worldwide roll-out of PromarkerD, and also facilitate the future commercialisation of our exciting pipeline of diagnostics under development,"* Dr Lipscombe said.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

**About Abcam plc** ([corporate.abcam.com](http://corporate.abcam.com))

Abcam (Cambridge, United Kingdom) (AIM:ABC and NASDAQ:ABCM) is a global life sciences company focused on identifying, developing and distributing high-quality reagents and tools for customers. Headquartered in Cambridge, United Kingdom, Abcam operates across 13 locations around the world, supported by a world-class team of approximately 1,600 employees serving customers in over 130 countries. The company offers both high performance products and expert customer support at the forefront of life science research.

**About PromarkerD** ([www.PromarkerD.com](http://www.PromarkerD.com))

PromarkerD is a predictive test for the early detection of chronic kidney disease (CKD) in patients with type-2 diabetes. CKD is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant.

The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)).

In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. The PromarkerD immunoassay, the PromarkerD mass spectrometry assay, and the PromarkerD software hub have each achieved CE Mark registration in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)

**About Proteomics International Laboratories (PILL)** ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Corporate Advisor & Investor Relations  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@euroz.com](mailto:kmoss@euroz.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)